Santen Pharmaceutical , Ltd. Accounts Payable

The latest accounts payable for SNPHY is $27B as of June 2026. That compares with $42B in the prior-year period — down 36.3% year over year. Investors often review this figure alongside Santen Pharmaceutical , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SNPHY's accounts payable moved from $42B to $27B — a 36.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Santen Pharmaceutical , Ltd.'s operating scale or balance-sheet position.

A accounts payable figure of $27B for SNPHY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SNPHY's accounts payable ($27B), review year-over-year change from $42B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.